Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06840782 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Study acronym: OliGRAIL
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Sep 2025 to Sep 9, 2025v5
  2. Start date: Jun 2025 to Sep 2025v4
  3. Study sites: 1 to 3
    • Start date: May 2025 to Jun 2025
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Feb 2025 to Feb 2030
    • Start date: Feb 2025 to May 2025
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
Trial Details
NCT Number NCT06840782
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions
(from sponsor)		 Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov